Inhibition of matrix metalloproteinase expression by menatetrenone, a vitamin K2 analogue

Oncology Reports

Volumn 22, Issue 3, 2009, Pages 599-604

  Ide, Yasushi ^a   Zhang, Hao ^a,b   Hamajima, Hiroshi ^a   Kawaguchi, Yasunori ^a   Eguchi, Yuichiro ^a   Mizuta, Toshihiko ^a   Yamamoto, Kyosuke ^c   Fujimoto, Kazuma ^a   Ozaki, Iwata ^a  

^a SAGA UNIVERSITY   (Japan)

^b CHINA MEDICAL UNIVERSITY   (China)

^c Takagi Hospital   (Japan)

Author keywords

Hepatocellular carcinoma; Matrix metalloproteinase; Vitamin K2

Indexed keywords

GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MENATETRENONE; MITOGEN ACTIVATED PROTEIN KINASE; PHORBOL 13 ACETATE 12 MYRISTATE; STROMELYSIN; TRANSCRIPTION FACTOR AP 1; DRUG DERIVATIVE; FARNOQUINONE; PROTEIN KINASE C; PROTEINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; LIVER TUMOR; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASES; NF-KAPPA B; PROTEASE INHIBITORS; PROTEIN KINASE C; TETRADECANOYLPHORBOL ACETATE; TRANSCRIPTION FACTOR AP-1; VITAMIN K 2;

EID: 70349337194     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000478     Document Type: Article

References (39)

1. Llovet JM, Bourroghs A and Bruix J: Hepatocellular carcinoma. Lancet 362: 1907-1917, 2003.
2. Okuda K: Hepatocellular carcinoma. J Hepatol 32: 225-237, 2000.
3. Westermarck J and Kahari VM: Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 13: 781-792, 1999.
4. Okazaki I, Wada N, Nakano M, Saito A, Takasaki K, Doi M, Kameyama K, Otani Y, Kubochi K, Niioka M, Watanabe T and Maruyama K: Differences in gene expression for matrix metalloproteinase-1 between early and advanced hepatocellular carcinoma. Hepatology 25: 580-584, 1997.
5. Yamamoto H, Itoh F, Adachi Y, Sakamoto H, Adachi M, Hinoda Y and Imai K: Relation of enhanced secretion of active matrix metalloproteinases with tumor spread in human hepatocellular carcinoma. Gastroenterology 112: 1290-1296, 1997.
6. Arii S, Mise M, Harada T, Furutani M, Ishigami S, Niwano M, Mizumoto M, Fukumoto M and Imamura M: Overexpression of matrix metalloproteinase 9 gene in heopatocellular carcinoma with invasive potential. Hepatology 24: 316-322, 1996.
7. Ashida K, Nakatsukasa H, Higashi T, Ohguchi S, Hino N, Nouso K, Urabe Y, Yoshida K, Kinugasa N and Tsujii T: Cellular distribution of 92-kD type IV collagenase/gelatinase B in human hepatocellular carcinoma. Am J Pathol 149: 1803-1811, 1996.
8. Harada T, Arii S, Mise M, Imamura T, Higashitsuji H, Furutani M, Niwano M, Ishigami S, Fukumoto M, Seiki M, Sato H and Imamura M: Membrane-type matrix metalloproteinase-1 (MT1-MMP) gene is overexpressed in highly invasive hepatocellular carcinomas. J Hepatol 28: 231-239, 1998.
9. Ozaki I, Mizuta T, Zhao G, Yotsumoto H, Hara T, Kajihara S, Hisatomi A, Sakai T and Yamamoto K: Involvement of the Ets-1 gene in overexpression matrilysin in human hepatocellular carcinoma. Cancer Res 60: 6519-6525, 2000.
10. Ozaki I, Mizuta T, Zhao G, Zhang H, Yoshimura T, Kawazoe S, Eguchi Y, Yasutake T, Hisatomi A, Sakai T and Yamamoto K: Induction of matrix metalloproteinase genes in human hepatocellular carcinoma by hepatocyte growth factor via a transcription factor Ets-1. Hepatol Res 27: 288-300, 2003.
11. Furie B, Bouchard BA and Furie BC: Vitamin K-dependent biosynthesis of γ-carboxylglutamic acid. Blood 93: 1798-1808, 1999.
12. Shearer MJ: The roles of vitamin D and vitamin K in bone health and osteoporosis prevention. Proc Nutr Soc 56: 915-937, 1997.
13. Sakai I, Hashimoto S, Yoda M, Hida T, Ohsawa S, Nakajo S, and Nakaya K: Novel role of vitamin K2: a potent inducer of differentiation of various human myeloid leukemia cell lines. Biochem Biophys Res Commun 205: 1305-1310, 1994.
14. Wu FYH, Liao WC and Chang HM: Comparison of antitumor activity of vitamins K1, K2, K3 on human tumor cells by two (MTT and SRB) assays. Life Sci 52: 1797-1804, 1993.
15. Nishikawa Y, Carr BI, Wang M, Kars S, Finn F, Dowd P, Zheng ZB, Kerns J and Naganathan S: Growth inhibition of hepatoma cells induced by vitamin K and its analog. J Biol Chem 270: 28304-28310, 1995.
16. Mizuta T, Ozaki I, Eguchi Y, Yasutake T, Kawazoe S, Fujimoto K and Yamamoto K: The effect of menatetrenone, a vitamin K2 analog, on recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study. Cancer 106: 867-872, 2006.
17. Habu D, Shiomi S, Tamori A, Takeda T, Tanaka T, Kubo S and Nishiguchi S: Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA 292: 358-367, 2004.
18. Otsuka M, Kato N, Shao RX, Hoshida Y, Ijichi H, Koike Y, Taniguchi H, Moriyama M, Shiratori Y, Kawabe T and Omata M: Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. Hepatology 40: 243-251, 2004.
19. Yoshiji H, Kuriyama S, Noguchi R, Yoshii J, Ikenaka Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Masaki T and Fukui H: Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression. J Hepatol 42: 687-693, 2005.
20. Sakakima Y, Hayakawa A, Nagasaka T and Nakao A: Prevention of hepatocarcinogenesis with phosphatidylcholine and menaquinone-4: in vitro and in vivo experiments. J Hepatol 47: 83-92, 2007.
21. Leber TM and Balkwill FR: Zymography: a single-step staining method for quantitation of proteolytic activity on substrate gels. Anal Biochem 249: 24-28, 1997.
22. Mckay AR, Ballin M, Pelina MD, Farina AR, Nason AM, Hartzler JL and Thorgeirsson UP: Effect of phorbol ester and cytokines on matrix metalloproteinases and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines. Invasion Metastasis 18: 168-184, 1992.
23. Reifel-Miller AE, Conarty DM, Valasek KM, Iversen PW, Burns DJ and Birch KA: Protein kinase C isozymes differentially regulate promoters containing PEA3/12-O-tetradecanoyl-13-actate response element motifs. J Biol Chem 271: 21666-21671, 1996.
24. Ozaki I, Zhang H, Mizuta T, Ide Y, Eguchi Y, Yasutake T, Sakamaki T, Pestell RG and Yamamoto K: Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor κB activation. Clin Cancer Res 13: 2236-2245, 2007.
25. Hehner SP, Hofmann TG, Droge W and Schmitz ML: The anti-inflammatory sequiterpene lactone parthenoide inhibits NF-kappa B by tarteting the I kappa B kinase complex. J Immunol 163: 5617-5623, 1999.
26. Carr BI, Wang Z and Kar S: K vitamins, PTP antagonism, and cell growth arrest. J Cell Physiol 193: 263-274, 2002.
27. Tokita H, Tsuchida A, Miyazawa K, Ohyashiki K, Katayanagi S, Sudo H, Enomoto M, Takagi Y and Aoki T: Vitamin K2-induced antitumor effects via cell-cycle arrest and apoptosis in gastric cancer cell line. Int J Mol Med 17: 235-243, 2006.
28. Tsukioka T, Miura Y, Otsuki T, Nishimura Y, Hyodoh F, Wada H and Sugihara T: The mechanisms of vitamin K2-induced apoptosis of myeloma cells. Haematologica 91: 613-619, 2006.
29. Yokoyama T, Miyazawa K, Yoshida T and Ohyashiki K: Combination of vitamin K2 plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer cell lines. Int J Oncol 26: 33-40, 2005.
30. Sibayama-Imazu T, Sonoda I, Sakairi S, Aiuchi T, Ann W, Nakajo S, Itabe H and Nakaya K: Production of superoxide and dissipation of mitochondrial transmembrane potential by vitamin K2 trigger apoptosis in human ovarian cancer TYK-nu cells. Apoptosis 11: 1535-1543, 2006.
31. Bond M, Baker AH and Newby AC: Nuclear factor κB activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblast. Biochem Biophys Res Commun 264: 561-567, 1999.
32. Wroblewski LE, Noble PJM, Pagliocca A, Pritchard DM, Hart A, Campbell F, Dodson AR, Dockray GJ and Varro A: Stimulation of MMP-7(matrilysin) by Helicobacter pylori in human gastric epithelial cells: role in epithelial cell migration. J Cell Sci 116: 3017-3026, 2003.
33. Kanamori T, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Tsurumi H, Kojima S and Moriwaki H: Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells. Cancer Sci 98: 431-437, 2007.
34. Karin M: The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 270: 16483-16486, 1995.
35. Newton AC: Protein kinase C; structure, function and regulation. J Biol Chem 270: 28495-28498, 1995.
36. Mackay HJ and Tweleves CJ: Protein kinase C: a target for anticancer drugs? Endocrine-Related Cancer 10: 389-396, 2003.
37. Ventura JJ and Nebreda AR: Protein kinases and phosphatases as therapeutic targets in cancer. Clin Trans Oncol 8: 153-160, 2006.
38. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R and Kelley S: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5: 835-844, 2006.
39. Saxena SP, Fan T, Li M and Israels ED: A novel role for vitamin K1 in a tyrosine phosphorylation cascade during chick embryogenesis. J Clin Invest 99: 602-607, 1997.